Clinicopathological predictors of the presence of blood circulating tumor DNA in early-stage non-small cell lung cancers.

The implementation of lung cancer screening programs across the world has drawn considerable attention to improve early-stage lung cancer detection and prognostication. Several blood-based assays detecting circulating tumor DNA (ctDNA) recently emerged as non-invasive methods to detect malignancies. However, their limited sensitivity and predictive value remain a hurdle to their clinical use.